Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 4 bp deletion in exon 1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-PRKAR2A, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Protein Kinase A R2 (PKR2) also known as PRKAR2A is a regulatory subunit of Protein Kinase A (PKA). PKA is part of a larger complex known as the cAMP-dependent protein kinase which plays an important role in cellular signaling. PKA consists of regulatory and catalytic subunits with PKR2 serving as one of its regulatory forms. PKR2 possesses a molecular mass of approximately 47 kDa and is available in various human tissues with notable expression in the brain and cardiovascular system.
Biological function summary
PKR2 regulates the activity of PKA by binding to the catalytic subunit in the absence of cAMP therefore inhibiting its activity. When cAMP is present it binds to the regulatory subunit PKR2 leading to the release and activation of the catalytic subunit of PKA. PKR2 is an integral part of the PKA holoenzyme complex which plays a critical role in mediating cellular responses to hormonal stimulation.
Pathways
PKR2 is heavily involved in the cAMP-dependent signaling pathway. This pathway is essential for translating extracellular signals into cellular actions. It interacts with various effector proteins including adenylate cyclases and phosphodiesterases to modulate responses such as gene transcription metabolism and memory formation. PKR2-related activity influences pathways shared with proteins like the G-protein subunits which facilitate the effects of neurotransmitters.
PKR2 irregularities can impact conditions like heart failure and neurodegenerative diseases. Disrupted PKA pathway signaling involving PKR2 can contribute to cardiac dysfunction by affecting heart muscle contractility and hypertrophy. In neurodegenerative diseases the improper functioning of PKR2 can exacerbate disruptions in neural signaling. A connection exists between PKR2 and proteins such as CREB (cAMP response element-binding protein) which links PKR2's role to memory deficits observed in neurodegeneration.
